Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tito Fojo

Showing results (201-210 of 237) with videos related to

Pageof 24
Sort By:
Biorxiv : the Preprint Server for Biology|July 15, 2024
Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic adenocarcinomaMaryam Safari, Luigi Scotto, Agnes Basseville, et al.
The Journal of Clinical Investigation|October 16, 2023
Angiopoietin-2 blockade suppresses growth of liver metastases from pancreatic neuroendocrine tumors by promoting T cell recruitmentEunhyeong Lee, Sophie O'Keefe, Alessandra Leong, et al.
Cancer Medicine|March 9, 2021
Long-term outcomes in patients with advanced adrenocortical carcinoma after image-guided locoregional ablation or embolizationMichal Mauda-Havakuk, Elizabeth Levin, Elliot B Levy, et al.
European Radiology|June 27, 2023
Ethnic diversity in treatment response for colorectal cancer: proof of concept for radiomics-driven enrichment trialsLaurent Dercle, Melissa Yang, Mithat Gönen, et al.
Molecular Cancer Therapeutics|October 16, 2004
Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulinFrank Loganzo, Malathi Hari, Tami Annable, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
Phase I trial of a new schedule of romidepsin in patients with advanced cancersLaleh Amiri-Kordestani, Victoria Luchenko, Cody J Peer, et al.
Seminars in Oncology|November 24, 2019
A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamideHarshraj Leuva, Keith Sigel, Mengxi Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2010
A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancerRonan J Kelly, Deborah Draper, Clara C Chen, et al.
Anti-Cancer Drugs|February 9, 2018
Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lungSanjeeve Balasubramaniam, Christophe E Redon, Cody J Peer, et al.
The Oncologist|November 11, 2022
Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World DataCeline Yeh, Mengxi Zhou, Keith Sigel, et al.
Pageof 24

Showing results (201-210 of 237) with videos related to

Sort By:
Pageof 24
Biorxiv : the Preprint Server for Biology|July 15, 2024
Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic adenocarcinomaMaryam Safari, Luigi Scotto, Agnes Basseville, et al.
The Journal of Clinical Investigation|October 16, 2023
Angiopoietin-2 blockade suppresses growth of liver metastases from pancreatic neuroendocrine tumors by promoting T cell recruitmentEunhyeong Lee, Sophie O'Keefe, Alessandra Leong, et al.
Cancer Medicine|March 9, 2021
Long-term outcomes in patients with advanced adrenocortical carcinoma after image-guided locoregional ablation or embolizationMichal Mauda-Havakuk, Elizabeth Levin, Elliot B Levy, et al.
European Radiology|June 27, 2023
Ethnic diversity in treatment response for colorectal cancer: proof of concept for radiomics-driven enrichment trialsLaurent Dercle, Melissa Yang, Mithat Gönen, et al.
Molecular Cancer Therapeutics|October 16, 2004
Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulinFrank Loganzo, Malathi Hari, Tami Annable, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
Phase I trial of a new schedule of romidepsin in patients with advanced cancersLaleh Amiri-Kordestani, Victoria Luchenko, Cody J Peer, et al.
Seminars in Oncology|November 24, 2019
A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamideHarshraj Leuva, Keith Sigel, Mengxi Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2010
A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancerRonan J Kelly, Deborah Draper, Clara C Chen, et al.
Anti-Cancer Drugs|February 9, 2018
Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lungSanjeeve Balasubramaniam, Christophe E Redon, Cody J Peer, et al.
The Oncologist|November 11, 2022
Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World DataCeline Yeh, Mengxi Zhou, Keith Sigel, et al.
Pageof 24